Amneal Pharmaceuticals (AMRX) Retained Earnings (2017 - 2026)

Amneal Pharmaceuticals has reported Retained Earnings for 10 years, with the latest figure at $545.6 million in Q2 2026.

• On a quarterly basis, Retained Earnings rose 195.31% year-over-year to $545.6 million in Q2 2026; TTM through Jun 2026 was $545.6 million, a 195.31% increase from a year earlier, with the FY2025 full-year figure at $571.8 million, up 194.19% from the prior year.
• Retained Earnings was $545.6 million for Q2 2026 at Amneal Pharmaceuticals, up from $536.3 million in the prior quarter.
• The five-year high for Retained Earnings was $715.4 million in Q3 2023, with the low at -$607.1 million in Q4 2024.
• Average Retained Earnings over 5 years is $164.3 million, with a median of $542.4 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings plunged 212.58% in 2024, then surged 195.31% in 2026.
• Over 5 years, Retained Earnings stood at $691.6 million in 2022, then fell by 22.03% to $539.2 million in 2023, then slumped by 212.58% to -$607.1 million in 2024, then surged by 194.19% to $571.8 million in 2025, then slipped by 4.58% to $545.6 million in 2026.
• The last three Retained Earnings figures came in at $545.6 million (Q2 2026), $536.3 million (Q1 2026), and $571.8 million (Q4 2025), per Business Quant data.